Flavonols, a major subgroup of the flavonoids, are polyphenolic molecules widely found in fruits and vegetables [1, 2] . Flavonols exert a variety of biological activities including antioxidant, anti-inflammatory and vasorelaxant effects [3, 4] which are all believed to contribute to their capacity to decrease the incidence of cardiovascular disease [5] [6] [7] [8] [9] [10] [11] [12] .
Whilst considerable attention has been paid to the antioxidant activity of flavonols as a major contributor to their cardioprotective actions, there is growing evidence of other properties that may be of importance. There have been several studies demonstrating that flavonols, particularly quercetin (Que), have anti-platelet aggregation activity that may also contribute to their beneficial effects [13] [14] [15] [16] . Several mechanisms of action have been proposed including inhibition of cyclooxygenase or phosphodiesterases [17] , antagonism of the TxA 2 receptor [18] [19] [20] , as well as more recent evidence showing inhibition of kinase activity [21] [22] [23] [24] . In particular, Que is reported to decrease Fyn and PI3 kinase activity and to inhibit tyrosine phosphorylation of Syk and PLCγ2 [21, 22] . Importantly when human subjects were treated with a single dose of Que (150 or 300 mg p.o.) there was a significant inhibition of platelet aggregation accompanied by inhibition of the same kinases observed in vitro [23] .
One study has demonstrated inhibition of collagen stimulated serotonin release from platelets following incubation with Que, suggesting inhibition of dense granule exocytosis [16] , but the effect on α-granules has not yet been explored.
Recently we have demonstrated that the synthetic flavonol 3', 4'-dihydroxyflavonol (DiOHF) is able to reduce injury after myocardial ischaemia and reperfusion [12, [25] [26] [27] and to improve endothelial function in diabetes [10] . As a structurally related molecule to Que, DiOHF may likewise inhibit platelet aggregation. However, the antiplatelet potential of DiOHF has not previously been explored.
While the functional impact of Que on the capacity of platelets to aggregate has been explored, it is not clear whether this relates to impaired activation of GPIIb/IIIa, impaired fibrinogen binding, granule exocytosis, or other mechanisms. Nor is it clear whether these reported antiplatelet activities can result in clinically relevant antithrombotic effects in vivo at achievable doses. Accordingly, the aims of this study were to elucidate and compare the effects of the flavonols Que and DiOHF on human platelet GPIIb/IIIa activation, fibrinogen binding and granule exocytosis in vitro, and arterial blood flow in an in vivo model of arterial thrombosis.
Methods

Human volunteers
RMIT University Human Ethics Committee approval and informed consent was obtained prior to blood collection. Subjects were healthy volunteers of both sexes, aged 18 -60 years with no history of vascular disease, bleeding disorders or thrombosis and had not taken aspirin or any other medication that affects platelet function for at least two weeks prior to the study.
Sample preparation
Blood collection was performed using established methods for platelet function studies [28, 29] . Briefly, fresh whole blood was collected by antecubital venepuncture into 3.8% (w/v) sodium citrate Vacuette tubes and used immediately for flow cytometric studies.
Platelet rich plasma (PRP) for platelet aggregation studies was obtained from the fresh blood after centrifugation at 200 x g for 10 min at room temperature. Platelet poor plasma (PPP) was obtained by centrifugation of the remaining blood at 1800 x g for 15 min at room temperature. Aggregation studies were completed within 3 hours of blood collection.
Platelet aggregation
The effect of Que, DiOHF (both sourced from Indofine Chemicals Inc, NJ. USA) or vehicle on agonist induced light transmittance platelet aggregation was determined. Flavonol samples were incubated with PRP at 37°C for 5 min to achieve concentrations ranging from 0.1 to 1.0 mM in 1 % (v/v) dimethyl sulfoxide (DMSO) (n = 3). Aggregation was stimulated by 5 µg.ml -1 collagen, 10 µM ADP and 0.5 mM AA (all agonists were sourced from Chrono-Log Co, USA). Turbidometric platelet aggregation was calibrated against a PPP control (100% aggregation) and the maximal aggregation over a 6 minute period was recorded. ATP release was measured in the presence of luciferin-luciferase reagent (Chrono-Log Co) against a 2 nM ATP standard by luminescence at 0.1 and 1.0 mM of Que or DiOHF.
Flow cytometric immunophenotyping
The effect of Que or DiOHF on platelet activation (measured by PAC-1 binding), α-granule exocytosis (measured by P-selectin expression and changes in surface CD61 expression with alpha granule release ) and fibrinogen binding was performed using established whole blood flow cytometric methods [28, 30, 31] . Fresh citrated whole blood from healthy volunteers (n = Dense granule exocytosis was quantitatively assessed by quinacrine uptake and thrombininduced release with flow cytometry as described previously [32] . Briefly, PRP from healthy human volunteers (n = 3) was incubated with quinacrine (100 µM) (Sigma, USA) at 37°C for 20 min in the dark, to allow quinacrine to be taken up by the dense granules. The platelets were then washed using 1 ml HEPES saline buffer and incubated with 1 mM Que or DiOHF at 37°C for 5 min. Thrombin (0.5 U.ml -1 , Chrono-Log Co) was then added and incubated at 37°C for 5 min. The reaction was stopped by 1:25 dilution in HEPES saline buffer and immediately read on the flow cytometer for 10,000 platelet events. The thrombin-induced decrease in quinacrine fluorescent intensity indicated dense granule release
Confocal laser scanning microscopy
The ability of platelet dense granules to release their contents was visualised using laser confocal imaging. PRP was incubated with (100 µM) quinacrine at 37°C in the dark and washed in HEPES saline buffer before incubation with Que or DiOHF (1 mM) at 37°C for 5 min. Exocytosis was stimulated by incubation with thrombin (0.5 U.ml -1 ) at 37°C for 5 min.
The reaction was stopped by 1:15 dilution in HEPES, and examined by confocal laser microscope (Nikon A1, Nikon Corp. Japan) using a 60x water immersion objective (NA 1.42) and excitation with a 488 nm laser, and NIS-Element advanced research software for image analysis. The proportion of platelets with fluorescent dense granules was quantified over a minimum of 5 fields per condition.
Animals
All experimental procedures performed in this study were approved by the Animal Experimentation Ethics Committee of RMIT University and in accordance with the guidelines of the Australian code of practice for the care and use of animals for scientific purposes.
Flavonol administration
Healthy C57BL/6 mice (13 week old of both sexes, body weight 20.9 ±0.47 g) were treated with a single intravenous (IV) bolus of Que (n = 5, 6 mg/kg), DiOHF (n = 5, 6 mg/kg) (Indofine chemicals Inc. USA), eptifibatide (n = 3, 4.5 mg/kg) (Millennium Pharmaceuticals, Japan) or vehicle (n = 5, DMSO plus polyethylene glycol and saline), using a 27 gauge needle via the tail vein. 30 min after administration of the treatment ferric chloride induced carotid artery damage was initiated.
Ferric Chloride Carotid injury model
Ferric chloride-induced arterial injury was performed using a well characterized model of platelet-mediated thrombosis [33] . In brief, C57BL/6 mice of both sexes were anaesthetised haematoxylin and eosin to demonstrate no visible difference in arterial injury between groups (data not shown).
Statistical analysis
All values are expressed as mean ± standard error of mean (SEM). Comparisons between samples from the same volunteer with aliquots spiked with flavonol or control were performed using one-way ANOVA with repeated measures and Dunnett's test, for post hoc comparisons. Comparisons between mice randomized to flavonol or control were performed using one-way ANOVA and Dunnett's test. Comparisons between Que and DiOHF were performed with Bonferroni post tests. Statistical analysis was performed using PRISM Graphpad software.
Results
Platelet aggregation
Incubation of PRP with Que or DiOHF inhibited platelet aggregation induced by 5 µg.mL 
Dense Granule Exocytosis
Dense granule exocytosis was measured by agonist induced ATP release and fluorescent quinacrine uptake and release. is shown in Figure 5 .
α-granule Exocytosis
α-granule exocytosis was measured by platelet surface P-selectin expression and agonist induced changes in GPIIIa expression.
1 mM Que significantly inhibited ADP (58% inhibition, p < 0.05), AA (36% inhibition, p < 0.05), TRAP (14% inhibition, p < 0.05), and adrenaline + collagen (54% inhibition, p < 0.05) induced α-granule exocytosis as measured by P-selectin mean fluorescence intensity ( Figure   6 ). Inhibition was observed with DiOHF also, but this failed to achieve statistical significance; ADP (25% inhibition, p = ns) AA (18% inhibition, p = ns), TRAP (3% inhibition, p = ns) adrenaline + collagen (31% inhibition, p = ns) ( Figure 6 ). 
Blood Flow Following Arterial Injury
Treatment with 6 mg/kg of Que or DiOHF better maintained blood flow when administered IV 30 min prior to initiation of platelet mediated thrombosis in the carotid artery compared to the vehicle control ( Figure 10A ). Vehicle treated mice had a 95% vessel occlusion at 15 min while the flavonol and eptifibatide treated mice had less than 20% vessel occlusion ( Figure   10B ).
Discussion
We have shown that both the naturally occurring flavonol Que, as well as a synthetic, An unexpected finding of this study was differences in the potency of inhibition of α-versus dense granule exocytosis by the two structurally related flavonols. Platelet α-granule secretion occurs more readily than dense granule secretion, however the mechanisms leading to membrane fusion and exocytosis of the two granule types have generally been assumed to be similar [34, 35] . Studies have shown that aspirin at certain concentrations is capable of inhibiting ADP induced serotonin release (a dense granule component) whilst P-selectin expression is unaffected [35] Recent studies have suggested that α-granules are heterogeneous in composition [34, 37] .
While all α-granules contain P-selectin, subtypes have been identified with differential expression of pro-and anti-angiogenic factors [37] and vWF [38] . While our results demonstrate that overall α-granule exocytosis, as measured by P-selectin expression, inhibited by Que, it remains possible that subtypes of α-granules may be uninhibited, and further studies are warranted to elucidate this.
Platelet exocytosis is a critical component of platelet function and thrombus growth, as it allows both the site specific release of pre-formed thrombo-inflammatory mediators, as well as alterations of the platelet surface membrane adhesion molecule and receptor expression [39] . The ability to modulate the inhibition of dense granule exocytosis relative to α-granule exocytosis by structural modification of flavonols represents a potential novel therapeutic target for antiplatelet therapy. Such an approach would inhibit release of ADP and serotonin, which are critical molecules involved in the positive feedback loop of platelet activation and thrombus propagation, whilst providing less inhibition of the capacity of platelets to activate, adhere to the site of injury, and deliver important immune and growth factor molecules from α-granules.
While a potential for different inhibition of dense and α-granule exocytosis by two structurally related flavonols is shown in this study, it is clear that this is in addition to antiplatelet effects of flavonols that have been previously described. Both flavonols effectively inhibited agonist induced aggregation in an independent manner, and delayed thrombus formation in an in vivo model of platelet mediated arterial thrombosis.
The concentrations of DiOHF and Que that were found to significantly inhibit collagen and ADP induced platelet aggregation were higher than previously reported by Sheu et al. [13] and Yin et al. [40] , but are consistent with Raghavendra et al. [15] . Because ADP, collagen and AA induced aggregation were all inhibited, these flavonols may inhibit platelet function by multiple mechanisms or a common pathway that is shared by these agonists. The ability of flavonols to inhibit kinase activity [16, [21] [22] [23] including Fyn and PI3 kinase activity and the tyrosine phosphorylation of Syk and PLCγ2 [16, 41, 42] may contribute to the inhibition of platelet activation, aggregation and granule exocytosis observed in this study. However, more potent inhibition of AA induced platelet aggregation suggest an additional mechanism may be through inhibition of cyclooxygenases [17] or binding to the thromboxane receptor [18, 43] as has been previously demonstrated.
A significant and novel finding in this study is that doses of these flavonols achievable in vivo were able to significantly improve blood flow following arterial injury in an in vivo model of platelet mediated thrombosis. In our well characterised model of platelet mediated arterial thrombosis ferric chloride initiates thrombus formation via iron mediated endothelial damage and platelet activation [33] . The significant improvements in blood flow following injury reported in this study suggest the potential for flavonols to be developed as a clinically relevant approach to inhibit platelet aggregation. However, ferric chloride induces oxidative injury, and flavonols have widely characterised antioxidant activity. While no visible difference in the magnitude of arterial injury was observed by histological examination of carotid artery (data not shown), it remains possible that administration of flavonols improved blood flow by affecting the nature of the ferric chloride induced oxidative injury, rather than by platelet mediated mechanisms. Further investigation using a crush injury model is warranted to verify this.
Limitations
In this study high concentrations of Que and DiOHF were used in order to demonstrate a novel mechanism of action of inhibition of different parameters of platelet function.
However, significant improvement in carotid blood flow in a model of platelet-mediated thrombosis was observed at much lower concentrations, indicating that incomplete inhibition of platelet function is necessary for improvement in arterial thrombosis in vivo. This is consistent with clinical benefits of partial platelet inhibition seen with established antiplatelet agents. Further studies are warranted to investigate whether structural modification might increase anti-platelet potency to achieve this novel mechanism of selective dense granule exocytosis more clinically achievable concentrations.
In order to achieve these high concentrations of flavonols in blood and plasma concentrations of up to 1% DMSO was necessary to maintain solubility. However, similar concentrations have been previously used without affecting parameters of platelet function [42] , and did not affect platelet function in response to the high concentrations of agonists used in this study (data not shown). Furthermore, appropriate 1% DMSO vehicle controls were used in the current study and no evidence of platelet toxicity was observed in aggregation tracings or flow cytometric dot plots.
Conclusion
These data provide the first evidence of inhibition of platelet activation, aggregation and granule secretion by DiOHF and report antithrombotic properties of both quercetin and 
